Indivior Pharmaceuticals, Inc. 13D

Oaktree Capital and affiliates have exited a >5% position in Indivior, now holding only about 0.76% via convertible notes, with this 13D/A filed as a non-activist exit amendment.

Oaktree Capital Holdings, LLC and affiliated funds filed Amendment No. 6 to their Schedule 13D on Indivior Pharmaceuticals, Inc. on 2026-08-13, disclosing that after substantial open-market sales of common stock and trades in the issuer’s 0.625% Convertible Senior Notes due 2031, they now beneficially own $37.872 million principal amount of Notes convertible into 909,053 shares, representing approximately 0.76% of Indivior’s common stock, and that as of August 10–11, 2026 they ceased to be beneficial owners of more than 5% of the stock, with this amendment serving as an exit filing and not indicating any activist or change‑of‑control intentions.

Filing Facts

CIK

1625297

Ticker

INDV

Form

13D

Source Type

fda

Accession

0001140361-26-032874

Alert Tier

8